<DOC>
	<DOCNO>NCT00777153</DOCNO>
	<brief_summary>The purpose study see effective cediranib treat brain tumour call recurrent glioblastoma . Two drug test study . Lomustine approve oral chemotherapy belongs class drug call alkylating agent . Cediranib new drug yet approve disease . This study compare use lomustine cediranib , cediranib alone lomustine placebo ( `` inactive substance '' ) see whether combination cediranib alone effective chemotherapy alone ( lomustine ) prevent growth cancer cell .</brief_summary>
	<brief_title>Cediranib Combination With Lomustine Chemotherapy Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Confirmation recurrent glioblastoma Life expectancy â‰¥ 12 week Received one prior systemic chemotherapy regimen regimen must contain temozolomide Patients enzymeinducing antiepileptic drug within 3 week prior randomisation Poorly control hypertension Previous antiangiogenesis ( eg bevacizumab , sorafenib , sunitinib ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Advanced Solid Tumour</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma</keyword>
</DOC>